Preclinical: IND/CTA Enabling

A seamless solution from start to finish.

Accelerating your drug into first-in-human trials in the USA and Europe requires the completion of an investigational new drug (IND) and clinical trial application (CTA), respectively. Both the FDA and EMA have different regulatory requirements, Abzena have the know how to meet this important milestone.

Contact Us

IND & CTA Enabling Expertise

IND- and CTA-enabling studies comprise preclinical pharmacology and manufacturing studies. These allow you to submit a formal application with the FDA or EMA. We accelerate the development of your medicines, de-risk your program, and reduce time to market by leveraging the extensive experience of our scientific and regulatory affairs experts.

We design and deliver tailored solutions across a comprehensive suite of services including, cell line development, formulation development, analytical method development and process development.

Contact Us

Preclinical IND/CTA Enabling Services

Preclinical activity is conducted through all phases of drug development. Therefore, we recognize that this activity needs to be fully integrated into a regulatory-driven, collaborative drug development strategy. With over 20 years of experience in drug development, we offer specialized preclinical IND/CTA enabling services.

Contact Us
Preclinical: IND/CTA Enabling Preclinical Bioconjugates & ADCs: IND & CTA Enabling

Latest News & Insights

Blog

Celebrating World Quality Month At Abzena

Read More

Articles

The Pharmaceutical Post: CDMO strategies for disrupting the biomanufacturing scale-up paradigm

Read More

Articles

The importance of GMP in ensuring the Quality and Safety of Complex Therapeutics

Read More